杭州市西湖区≥18岁人类免疫缺陷病毒感染者接种23价肺炎球菌多糖疫苗后不良事件观察  

Adverse events following vaccination with 23-valent pneumococcal polysaccharide vaccine among≥18-year-old individuals with human immunodeficiency virus infection:an observational study in Xihu district of Hangzhou city

作　　者：徐娜妮[1] 晏定燕 刘建宁 潘晓红 胡小炜[1,5] 喻剑华[2] 郑琳 张欣 Xu Nani;Yann Dingyan;Liu Jianning;Pan Xiaohong;Hu Xiaowei;Yu Jianhua;Zheng Lin;Zhang Xin(Xihu District Center for Disease Control and Prevention,Hangzhou 310030,Zhejiang,China;Xixi Hospital of Hangzhou,Hangzhou 310023,Zhejiang,China;Zhejiang Association for STD and AIDS Prevention and Control,Hangzhou 310051,Zhejiang,China;Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310051,Zhejiang,China;Xihu District Public Health Research Institute,Hangzhou 310013,Zhejiang,China;Hangzhou Medical College,Hangzhou 310053,Zhejiang,China)

机构地区：[1]杭州市西湖区疾病预防控制中心,浙江杭州310030 [2]杭州市西溪医院,浙江杭州310023 [3]浙江省性病艾滋病防治协会,浙江杭州310051 [4]浙江省疾病预防控制中心,浙江杭州310051 [5]杭州市西湖区公共卫生研究院,浙江杭州310013 [6]杭州医学院,浙江杭州310053

出　　处：《中国疫苗和免疫》2024年第4期466-469,共4页Chinese Journal of Vaccines and Immunization

摘　　要：目的 评价人类免疫缺陷病毒(Human immunodeficiency virus, HIV)感染者接种23价肺炎球菌多糖疫苗(23-valent pneumococcal polysaccharide vaccine, PPV23)后不良事件发生率。方法 在杭州市西湖区某接种门诊入组≥18岁HIV感染者,观察接种1剂次PPV23后0-28 d不良事件,分析发生率。结果 受试者接种1剂次PPV23后0-28 d总不良事件发生率为32.89%(148/450),其中局部、全身不良事件发生率分别为31.33%(141例)、2.22%(10例);接种部位疼痛、红肿、硬结发生率分别为24.89%(112例)、7.33%(33例)、10.00%(45例);发热、头晕发生率分别为2.00%(9例)、0.22%(1例);未观察到严重不良事件。结论 本研究显示≥18岁HIV感染者接种PPV23后不良事件发生率在预期范围内且症状轻微。Objective To determine incidences of adverse events following vaccination with 23-valent pneumococcal polysaccharide vaccine(PPV23) in ≥18-year-old individuals living with human immunodeficiency virus(HIV).Methods We enrolled HIV-infected adults over 18 years of age from vaccination clinics in Xihu district of Hangzhou city and followed them up for adverse events 0-28 days after receiving one dose of PPV23 to determine incidences.Results The overall incidence of adverse events 0-28 days after one dose of PPV23 vaccination was 32.89%(148/450), with local and systemic adverse event rates of 31.33%(141 cases) and 2.22%(10 cases). Incidences for injection-site pain, redness, and swelling were 24.89%(112 cases), 7.33%(33 cases), and 10.00%(45 cases). Incidences for fever and dizziness were 2.00%(9 cases) and 0.22%(1 case). No serious adverse events were reported.Conclusion The incidence of adverse events following PPV23 vaccination of people ≥18 years of age living with HIV was less than expected, and symptoms of adverse events were mild.

关 键 词：23价肺炎球菌多糖疫苗 预防接种 不良事件 人类免疫缺陷病毒感染 

分 类 号：R186[医药卫生—流行病学]